NasdaqGM:ZLABBiotechs
China’s TIVDAK Approval in Advanced Cervical Cancer Could Be A Game Changer For Zai Lab (ZLAB)
Zai Lab Limited recently announced that China’s National Medical Products Administration approved the Biologics License Application for TIVDAK (tisotumab vedotin) to treat adult patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy, based on the Phase 3 innovaTV 301 trial showing an overall survival benefit and no new safety signals in the China subpopulation.
This approval gives Zai Lab exclusive rights to commercialize TIVDAK across Greater...